


(S)-TV-45070

- A novel analgesic developed by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical, 2012-2018)
- An antagonist of the Na<sub>v</sub>1.7 sodium ion channel protein
- Currently in Phase II trials for Postherpetic neuralgia (PHN)
- Have potential therapeutic value for chronic pain caused by alterations in Na<sub>v</sub>1.7 or corresponding encoding gene SCN9A



Sclafani, J. A. *Org. Process Res. Dev.* **2017**, *21*, 1616. <https://doi.org/10.1021/acs.oprd.7b00237>

### First-generation process route




- Large-scale chromatography to purify the crude racemic compound required
- Significant losses due to late stage resolution
- Genotoxic bromomethylfuran used in late stage

Cardieux, J. J. U.S. Patent 8,445,696, May 21, 2013.

(S)-TV-45070


### Simulated moving bed (SMB) chromatography




- The liquid phase is in motion and the solid phase moves in counter-current mode to the liquid phase.
- The feed (component A+B) is injected in the middle of the demonstrated SMB column.
- The liquid phase transports component A (blue), which is led out of the system in the raffinate as a pure substance.
- The solid phase transports component B (red), which is guided out as an extract.
- Contrary to the traditional chromatographic separation in a single column, the entire column bed is efficiently used.

Lieres, E. *Comput. Chem. Eng.* **2018**, *111*, 183. <https://doi.org/10.1016/j.compchemeng.2017.12.022>


First-generation asymmetric route



Asymmetric aldol reaction with unprotected phenol 1



**Asymmetric aldol reaction with protected phenol intermediate**



catalyst	solvent	time (h)	<b>3</b> (A%)	<b>3a</b> (A%)	ee of <b>3</b> (%)
(DHQ) <sub>2</sub> PHAL	CH <sub>2</sub> Cl <sub>2</sub>	113	30	62	27
(DHQ) <sub>2</sub> PHN	CH <sub>2</sub> Cl <sub>2</sub>	90	41	47	27
(DHQ) <sub>2</sub> PHN	THF	90	35	56	13
<b>B</b>	CH <sub>2</sub> Cl <sub>2</sub>	18	87	9	33
<b>B</b>	THF	18	77	13	32
<b>B</b>	toluene	18	91	3.9	10
<b>B</b>	CH <sub>3</sub> CN	18	92	3.2	25
<b>C</b>	toluene	21	92.7	3.2	17
<b>C</b>	THF	21	71.5	25.9	30
<b>C</b>	CH <sub>2</sub> Cl <sub>2</sub>	18	82	7.1	35

catalyst	solvent	time (h)	<b>4</b> (A%)	<b>5</b> (A%)	ee of <b>5</b> (%)
<b>C</b>	CH <sub>3</sub> CN	18	30	70	45
<b>C</b>	CH <sub>3</sub> CN*	18	28	72	50
<b>C</b>	<b>heptane</b>	<b>18</b>	<b>5</b>	<b>95</b>	<b>73</b>
<b>C</b>	heptane*	18	29	71	54
<b>B</b>	heptane	18	2	98	58
<b>B</b>	CH <sub>3</sub> CN	18	2.7	97.3	36
<b>B</b>	THF	40	18	82	41
<b>B</b>	toluene	18	32	68	54

\*Performed using 30 mL/g versus 10 mL/g

**Optimized plant synthesis**

